CVOT Summit 2025 puts the cardiovascular-kidney-metabolic continuum at the center of trial design
The 11th Cardiovascular Outcome Trial Summit, held virtually on November 20-21, 2025, framed one of the year’s most important shifts in cardiometabolic medicine: the move from single-disease thinking toward the cardiovascular-kidney-metabolic continuum. The program brought together investigators and clinicians from endocrinology, diabetology, cardiology, nephrology, hepatology, and general practice to examine how outcome trials are beginning to reflect the biology seen at the bedside, where heart failure, chronic kidney disease, diabetes, obesity, and metabolic liver disease rarely appear in isolation.
The report centers on several developments that define the current direction of the field. Among them are the first head-to-head cardiovascular outcome trial, SURPASS-CVOT, the expanding evidence base for combination therapy, fresh attention to inflammatory mechanisms within CKM syndrome, and policy discussions that now sit closer to the center of therapeutic decision-making than they did only a few years ago. The science is no longer confined to whether one agent lowers glucose, blood pressure, or albuminuria. The question is how therapies can be combined, sequenced, and deployed early enough to alter multi-organ risk.
One sharp feature of the 2025 discussion was the emphasis on therapies that cross traditional specialty boundaries. A drug affecting renal hemodynamics may also reshape cardiovascular risk; a glucose-lowering agent may alter body weight, heart failure risk, and kidney trajectory; an intervention aimed at aldosterone biology may affect vascular and renal stress at the same time. The CKM framework captures that overlap better than older siloed models, and the Summit used that lens to organize the most recent clinical advances.
Combination therapy moved from concept to trial evidence
A major portion of the report focused on CONFIDENCE, which examined combination therapy with finerenone and empagliflozin. The importance of this trial extends beyond any single drug class. In clinical practice, the same patient often arrives with diabetic kidney disease, hypertension, heart failure risk, and residual cardiorenal risk despite standard therapy. A combination strategy is biologically plausible because it attacks different axes of injury: mineralocorticoid receptor signaling on one side, and sodium-glucose cotransporter 2 inhibition on the other.
That approach matters because CKM disease rarely advances along one pathway only. Renal inflammation, hemodynamic stress, fibrosis, sodium retention, endothelial dysfunction, and metabolic toxicity can reinforce each other for years. A paired regimen designed to interrupt more than one of those pathways is consistent with the pathophysiology, even before downstream outcome data are fully matured.
Oral GLP-1 therapy and the move toward less invasive metabolic treatment
The report also reporting ATTAIN-1, which evaluated the oral GLP-1 receptor agonist orforglipron. Oral delivery remains clinically important because route of administration can determine whether a therapy reaches the people who need it most. Injectable therapies are effective, but barriers to initiation and persistence remain real in routine care. An oral GLP-1 receptor agonist changes the practical reach of incretin-based treatment, particularly in long-term management of obesity and related metabolic disease.
The Summit’s focus on orforglipron signals a broader shift in metabolic pharmacology. The field is no longer asking only whether a GLP-1 agent works. It is asking how to integrate incretin biology into care pathways that also involve kidney protection, cardiovascular prevention, and liver disease management. In patients with overlapping metabolic disorders, the possibility of a non-injectable GLP-1 option raises the bar for accessibility, adherence, and durable implementation.
Aldosterone biology remained a central theme in blood pressure control
The aldosterone synthase inhibitor baxdrostat, discussed through BaxHTN, brought endocrine hypertension into sharper focus. Excess aldosterone is not a niche mechanism; it contributes to vascular stiffness, sodium retention, potassium handling, and end-organ injury. In resistant or difficult-to-control hypertension, suppressing aldosterone synthesis rather than simply blocking its receptor may offer a different therapeutic logic, especially when blood pressure remains a driver of renal and cardiovascular damage.
This line of investigation matters in CKM disease because blood pressure control is not only a surrogate endpoint. It is one of the few modifiable forces that directly shapes stroke risk, heart failure burden, kidney decline, and the cumulative injury sustained by the arterial tree. A therapy that changes the hormonal engine behind hypertension has implications that extend well beyond a single clinic reading.
Inflammation moved closer to the center of CKM biology
A particularly important thread running through the Summit was the inflammatory component of CKM syndrome. Inflammation is not an abstract biological add-on; it is part of the tissue-level injury that drives plaque instability, glomerular damage, hepatic fibrosis, and vascular dysfunction. By treating inflammation as a core pathogenic feature rather than a secondary observation, investigators are broadening the therapeutic target list for cardiometabolic disease.
This perspective helps explain why the Summit placed emphasis on outcome trials that do more than lower glucose or blood pressure alone. A therapy can be metabolically active and still miss the inflammatory biology that drives irreversible organ damage. The new generation of studies reflects that understanding, especially where residual risk persists despite standard-of-care treatment.
Policy, guidelines, and monitoring technology are now part of the same discussion
The report also covered guideline and policy developments discussed across specialties, along with advances in medical technology, especially continuous glucose and ketone monitoring. Those tools matter because treatment can only be individualized when clinicians can see physiology in real time. Continuous monitoring changes the cadence of decision-making in diabetes care and, by extension, in broader CKM management where metabolic stability and safety monitoring are tightly linked.
The inclusion of medical technology in the Summit agenda reflects a practical truth about modern chronic disease care: pharmacology and monitoring now evolve together. Better sensors can support safer titration, identify gaps in control earlier, and help clinicians respond before organ injury becomes entrenched. In complex CKM patients, that kind of feedback loop is increasingly relevant.
The 2026 summit arrives with more questions than final answers
The 12th Cardiovascular Outcome Trial Summit is scheduled for November 19-20, 2026. Until then, the field will continue to test whether combination therapy, endocrine modulation, oral incretin strategies, and earlier intervention can change long-term outcomes across the CKM spectrum.
What remains unresolved is not whether these mechanisms matter, but how best to sequence them in routine care, which patients should receive combination therapy earliest, and how emerging options will compare once outcome data mature across competing drug classes. The next wave of trial readouts will need to answer those questions with the same discipline now visible in the Summit agenda.